The UK showcases a commitment to advancing Next-Generation Sequencing (NGS) technology with well-established infrastructure and sufficient funding. Routine NGS utilization in clinical and research practices reflects widespread integration. However, the absence of a dedicated molecular tumor board suggests a need for improved collaborative discussions in patient management.

The UK boasts a well-trained healthcare workforce for NGS testing and prioritizes data security and integration into Electronic Health Records (EHR) with governance in place. While emphasizing responsible data-sharing practices, cross-border collaborations remain less prevalent.

For the comprehensive factsheet, find the download button below.